Lilly slashes clinical trial activities in response to COVID-19
Monday, March 23, 2020
Eli Lilly is slashing its clinical trial activities in response to the COVID-19 pandemic. With the novel coronavirus putting healthcare systems under tremendous strain, Lilly has decided to delay most trial starts and pause enrollment in most ongoing studies.
No comments:
Post a Comment